glp-1 obesity drug news today september 15 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections for these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ Bariatric Surgery vs. GLP-1 Drugs

In fact, the Brighton and, perhaps, Villefranche criteria for JHS/EDS-HT are met more commonly by females with a markedly skewed sex ratio [18]

"I think its often hard for people to admit using these products to a medical professional, so its difficult to ascertain the extent of usage," Dr

Existing studies evaluating CD8 + T-cell changes in adipose tissue were primarily based on obese models, and studies on mechanisms of aging-related changes are limited

Mean body weight changes across the groups at the end of 32 weeks were: CagriSema: 15.6% Semaglutide alone: 5.1% Cagrilinitide alone: 8.1% [43] Side effects included nausea (29% of patients), diarrhea (16%) and vomiting (10%) in CagriSema treated patients